Highlighted Stocks: FirstEnergy Corp. (NYSE:FE), Sabra Health Care REIT (NASDAQ:SBRA), ViaSat (NASDAQ:VSAT), Ironwood Pharmaceuticals (NASDAQ:IRWD)

Tri Pointe Homes Inc (NYSE:TPH) shares moved up 0.97% in last trading session and ended the day at $12.46. TPH Gross Margin is 23.10% and its has a return on assets of 6.70%. Tri Pointe Homes Inc (NYSE:TPH) quarterly performance is 22.28%.

FirstEnergy Corp. (NYSE:FE) ended the last trading day at $34.39. Company weekly volatility is calculated as 2.24% and price to cash ratio as 109.67. FirstEnergy Corp. (NYSE:FE) showed a weekly performance of -3.13%.

FirstEnergy Corp. (NYSE:FE) reported first quarter 2016 operating (non-GAAP) earnings of $0.80 per basic share of common stock. These results exclude the impact of the special items and compare to first quarter 2015 operating (non-GAAP) earnings of $0.62 per basic share of common stock.

On 26 April, Sabra Health Care REIT, Inc. (NASDAQ:SBRA) shares moved up 1.85% and was closed at $20.95. SBRA EPS growth in last 5 year was 37.91%. Sabra Health Care REIT, Inc. (NASDAQ:SBRA) year to date (YTD) performance is 6.33%.

Sabra Health Care REIT, Inc. (NASDAQ:SBRA) announced that it will issue its 2016 first quarter earnings release after close of market on May 2, 2016.

ViaSat Inc. (NASDAQ:VSAT) shares moved up 1.30% in last trading session and ended the day at $76.55. VSAT Gross Margin is 31.00% and its has a return on assets of 1.10%. ViaSat Inc. (NASDAQ:VSAT) quarterly performance is 25.53%.

On1 8 April, ViaSat Inc. (NASDAQ:VSAT), announced it received Supplemental Type Certificate (STC) approval from the FAA to install its advanced Ka-band satellite antenna and radome on Airbus A320 aircraft. This certification, coupled with ViaSat’s in-cabin distribution STC, enables airlines to deploy ViaSat’s complete end-to-end in-flight connectivity system, giving passengers access to the industry’s fastest, highest capacity in-flight internet service.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) caters to the Healthcare space. It has a net profit margin of -95.40% and weekly performance is -7.07%. On the last day of trading company shares ended up at $10.25.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced that it has entered into a licensing agreement with AstraZeneca plc for the exclusive U.S. rights to lesinurad. Lesinurad 200mg tablets were approved as ZURAMPIC® by the U.S. Food and Drug Administration (FDA) in December 2015 for use in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout.